Atrandi Biosciences expands leadership team to accelerate global adoption of capsule-based single-cell technology. May 18, 2026 Company appoints Sam Ropp as Chief Commercial Officer and Susan Tousi to Board of Directors BOSTON - May 19, 2026 - Atrandi Biosciences, a life science tools company pioneering Semi-Permeable Capsule (SPC) technology for single-cell and multiomics research, today announced the appointment of Sam Ropp, PhD, as Chief Commercial Officer and Susan Tousi as Chairman of the Board of Directors. These additions strengthen Atrandi's leadership team as the company accelerates global adoption of its capsule-based single-cell platform designed to enable complex, multi-step molecular workflows at single-cell resolution beyond the limitations of traditional droplet approaches. "The deep expertise and proven leadership Sam and Susan bring in commercial strategy and operational excellence will be instrumental as we accelerate our mission to make complex single-cell experiments practical, repeatable, and accessible in everyday laboratories," said Juozas Nainys, PhD, Chief Executive Officer at Atrandi Biosciences. "Sam's experience scaling innovative life science platforms and Susan's strategic insight into global market development will help us bring SPC technology to scientists worldwide." As Chief Commercial Officer, Dr. Ropp will lead Atrandi's global commercial strategy, including sales, service, field applications, marketing, and strategic partnerships. He joins Atrandi with more than two decades of experience scaling life science technology platforms and building high-performing commercial organizations. Dr. Ropp previously held senior leadership roles at Singular Genomics, 10x Genomics, BD, Molecular Devices, and Bio-Rad Laboratories, where he helped bring innovative research technologies from early adoption to global market expansion, including the commercialization of widely adopted single-cell platforms. Throughout his career, he has focused on translating complex scientific tools into scalable commercial solutions that accelerate discovery for researchers and clinicians. "I'm excited to join Atrandi at a moment when single-cell analysis can move beyond single-modality experiments toward a more integrated, multiomic understanding of what's driving biology," said Dr. Ropp. "Scientists' understanding of single-cell biology has long been constrained by the limitations of existing workflows. SPC technology unlocks a level of experimental flexibility that scientists simply haven't had with traditional single-cell approaches. Our focus now is building the commercial engine and partnerships that bring that capability to labs around the world." Susan Tousi joins the board with more than 30 years of experience in imaging, genomics, diagnostics, and biotechnology, having served in senior executive and board roles at leading organizations. She is a leader in technology and product development who was inducted into the National Academy of Engineers and has developed and scaled multi-billion-dollar businesses. She is currently CEO of Delfi Diagnostics and was previously Chief Commercial Officer and Senior Vice President and Chief Product Officer, at Illumina. "The demand for more flexible and scalable single-cell analysis technologies continues to grow globally, and Atrandi's proprietary SPC technology offers significant advantages over existing droplet-based and other single-cell analysis platforms," said Ms. Tousi. "I look forward to working with the board and leadership team to help Atrandi scale strategically and translate its technological leadership into broader adoption across research and translational applications." Atrandi's patented Semi-Permeable Capsule (SPC) technology represents a new class of single-cell workflow infrastructure designed to enable complex multi-step molecular biology at scale. SPCs are microcapsules consisting of a liquid core surrounded by a thin crosslinked hydrogel shell with size-selective permeability. Small molecules such as salts, buffers, enzymes, primers, and antibodies can diffuse freely across the capsule shell, while cells, genomic DNA, and larger molecular complexes remain contained within. This architecture allows researchers to wash, exchange, and stage multiple biochemical reactions while preserving single-cell identity throughout the process. By combining the flexibility of well-based workflows with the throughput of droplet-based systems, SPC technology enables scientists to perform bulk-like molecular reactions at single-cell resolution across diverse experimental designs. About Atrandi Biosciences Atrandi Biosciences is a life science tools company advancing single-cell analysis with its patented Semi-Permeable Capsule (SPC) technology, enabling scalable multi-step workflows that preserve single-cell identity across sequential chemistry. Headquartered in Vilnius, Lithuania, Atrandi supports researchers worldwide with commercially available SPCs, workflow kits, and instruments. Its name, meaning "you discover" in Lithuanian, reflects the company's purpose: helping scientists uncover what biology keeps hidden. For more information, visit www.atrandi.com.

Tecan Group AG stock (CH0012100191): Lab automation leader eyes US growth. 13.05.2026 - 20:29:07 | ad-hoc-news.de Tecan Group AG, a Swiss lab automation specialist, strengthened US ties through a July 2025 collaboration with Singular Genomics on NGS kits, amid booming demand in diagnostics and life sciences. Tecan Group AG recently collaborated with Singular Genomics Systems, Inc., a US-based firm, to develop customized reagent kits for next-generation sequencing (NGS) library preparation. The partnership, announced in July 2025, targets enhanced automation in genomics workflows, according to MarketsandMarkets as of July 2025. Tecan shares trade on the SIX Swiss Exchange under ticker TECN. As of: 13.05.2026 By the editorial team - specialized in equity coverage. At a glance. * Name: Tecan Group AG * Sector/industry: Life sciences equipment / lab automation * Headquarters/country: Männedorf, Switzerland * Core markets: US, Europe, Asia * Key revenue drivers: Liquid handling systems, automation platforms * Home exchange/listing venue: SIX Swiss Exchange (TECN) * Trading currency: CHF Official source For first-hand information on Tecan Group AG, visit the company's official website. Tecan Group AG: core business model. Tecan Group AG develops and manufactures laboratory automation solutions for life sciences, diagnostics, and biopharma. Its platforms enable high-throughput screening, genomics, and drug discovery, serving academic, biotech, and pharmaceutical customers worldwide. The company reported strong positioning in automated liquid handling, a key segment per industry analyses. Headquartered in Switzerland, Tecan operates globally with significant US exposure through sales and partnerships. Its OEM business supplies components to major diagnostics firms, contributing to diversified revenue streams. Main revenue and product drivers for Tecan Group AG. Tecan's revenue stems primarily from its Life Sciences and Partnering Business segments. Liquid handling workstations like the Fluent and Freedom platforms drive demand in research automation. In diagnostics, OEM partnerships provide steady income, with the US market representing a core growth area for US investors tracking medtech innovation. The July 2025 collaboration with Singular Genomics underscores Tecan's role in NGS workflows, aligning with rising US demand for decentralized testing and personalized medicine, as noted in IndexBox market outlook. Industry trends and competitive position. The lab automation market is projected to expand through 2031, fueled by AI integration and high-throughput needs in genomics. Tecan competes with Thermo Fisher Scientific, Danaher, and Agilent, holding leadership in liquid handling per MarketsandMarkets evaluations. Its focus on modular systems differentiates it in a fragmented sector. For US investors, Tecan's exposure to American biotech hubs like Boston and San Francisco offers indirect play on US life sciences R&D spending, which tops global charts. Why Tecan Group AG matters for US investors. Listed on the SIX Swiss Exchange, Tecan provides US retail investors access via ADRs or international brokers to Europe's medtech strength. With US collaborations like Singular Genomics and presence in diagnostics CDMOs, it ties into American trends in precision medicine and outsourced manufacturing. Additional news and developments on the stock can be explored via the linked overview pages. Conclusion. Tecan Group AG continues to leverage its automation expertise amid lab digitization trends, with recent US partnerships highlighting growth potential. While market competition persists, its diversified segments and global footprint support ongoing relevance. Investors should monitor upcoming earnings for updates on NGS and diagnostics momentum. Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments. Tecan stock: new analysis - 15 may. Fresh Tecan information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Seit 2005 liefert der Börsenbrief trading-notes verlässliche Anlage-Empfehlungen - dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren. Für. Immer. Kostenlos. en | CH0012100191 | TECAN | boerse | 69327423 | bgmi